# Randomized Evaluation of Istaroxime for Stabilization in Acute Heart Failure-Cardiogenic Shock

Study · id `cardio:ct-nct07583446` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07583446](<https://clinicaltrials.gov/study/NCT07583446>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT07583446

Browse, organ or system: Heart  
Browse, condition area: Acute care and long-term living  

## In plain language

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 600 participants.

## Technical summary

Registry record NCT07583446. Randomized; quadruple masking; primary purpose treatment. Start 2026-09-09 (actual); primary completion 2028-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2/3
- Enrolled: 600 participants (planned count; ClinicalTrials.gov record NCT07583446, source copy `cardio:ctgov-nct07583446-2026-09-23`, retrieved 2026-10-31)
- Started: 2026-09-09 (actual) (ClinicalTrials.gov record NCT07583446, source copy `cardio:ctgov-nct07583446-2026-09-23`, retrieved 2026-10-31)
- Primary completion: 2028-12 (anticipated) (ClinicalTrials.gov record NCT07583446, source copy `cardio:ctgov-nct07583446-2026-09-23`, retrieved 2026-10-31)
- Completion: 2028-12 (anticipated) (ClinicalTrials.gov record NCT07583446, source copy `cardio:ctgov-nct07583446-2026-09-23`, retrieved 2026-10-31)
- Countries: Armenia (ClinicalTrials.gov record NCT07583446, source copy `cardio:ctgov-nct07583446-2026-09-23`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07583446-2026-09-23`, retrieved 2026-10-31)

## The registry's words

- Brief title: Randomized Evaluation of Istaroxime for Stabilization in Acute Heart Failure-Cardiogenic Shock
- Acronym: RESCUE HF-CS
- Condition: Cardiogenic Shock
- Intervention (Drug): istaroxime
- Intervention (Drug): placebo
- Lead sponsor: Seismic Pharmaceuticals Operations LLC
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Cardiogenic shock (`cardio:cardiogenic-shock`)

## Provenance

Content hash: 43b2a51f3a97f22ff0e9e05e043ddfa73f8029430bbdc3dbc15c463261b242d0
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
